Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro

Article ID	Journal	Published Year	Pages	File Type
8523956	Biochemical Pharmacology	2018	32 Pages	PDF

Keywords

FDA DNR CDKI basolateral-to-apical apical-to-basolateral Mitoxantrone ABCC1 ABCB1 XTT ABC DDI qRT-PCR ITC EMA CDK MDCKII ABCG2 CyP PMS DMEM 95%CI ER+European Medicines agency US Food and Drug Administration mit drug-drug interaction Pharmacokinetic interactions ABC transporters Daunorubicin Ribociclib Cytochrome P450 combination index phenazine methosulfate Dulbecco’s modified eagle’s medium Multidrug resistance cyclin-dependent kinase inhibitor quantitative reverse-transcription polymerase chain reaction Multidrug Resistance-associated Protein 1 breast cancer resistance protein Madin-Darby canine kidney ATP-binding cassette cyclin-dependent kinase estrogen receptor positive

Related Topics

Health Sciences Pharmacology, Toxicology and Pharmaceutical Science Pharmacology

Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro

Authors

Ales Sorf, Jakub Hofman, Radim KuÄera, Frantisek Staud, Martina Ceckova,